Swan Gary E, McAfee Tim, Curry Susan J, Jack Lisa M, Javitz Harold, Dacey Sara, Bergman Katherine
Center for Health Sciences, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA.
Arch Intern Med. 2003 Oct 27;163(19):2337-44. doi: 10.1001/archinte.163.19.2337.
The efficacy of bupropion hydrochloride sustained release (SR) (Zyban) for smoking cessation has been evaluated in clinical trials that included frequent in-person behavioral counseling, but not in actual practice settings.
To determine the differential effectiveness of 2 doses of bupropion SR in combination with behavioral interventions of minimal to moderate intensity in an actual practice setting.
Open-label randomized trial, with 1 year of follow-up.
A large health system (Group Health Cooperative) based in Seattle.
Adult smokers (N = 1524) interested in quitting smoking.
Participants were randomly assigned to receive 1 of 4 combinations of bupropion SR (150 or 300 mg) and behavioral counseling (minimal or moderate intensity).
The primary outcome measure was self-reported point-prevalence 7-day nonsmoking status at 3 and 12 months following the target quit date. Secondary outcomes included adverse and abstinence effects reported since beginning treatment with bupropion SR.
At 3 months, a significantly higher rate of nonsmoking was observed among those receiving the larger bupropion SR dose (P=.005). At 12 months, moderate intensity counseling was associated significantly with a higher rate of nonsmoking (P=.001). At 3 months, the higher dose was associated with a significantly increased frequency of self-reported symptoms such as difficulty sleeping (P=.02), difficulty concentrating (P=.02), shakiness/tremor (P=.002), and gastrointestinal problems (P=.005)and a decreased frequency of reported desire to smoke (P=.001).
In this actual practice setting, the combination of bupropion SR and minimal or moderate counseling was associated with 1-year quit rates of 23.6% to 33.2%. This suggests that existing health care systems can substantially decrease tobacco use rates among their enrollees if they provide these modest interventions.
盐酸安非他酮缓释片(Zyban)用于戒烟的疗效已在临床试验中得到评估,这些试验包括频繁的面对面行为咨询,但未在实际临床环境中进行评估。
确定在实际临床环境中,两种剂量的盐酸安非他酮缓释片与最低至中等强度行为干预相结合的差异有效性。
开放标签随机试验,随访1年。
西雅图的一个大型医疗系统(健康合作组织)。
有戒烟意愿的成年吸烟者(N = 1524)。
参与者被随机分配接受盐酸安非他酮缓释片(150或300毫克)与行为咨询(最低或中等强度)的四种组合之一。
主要观察指标是在目标戒烟日期后3个月和12个月时自我报告的7天点患病率戒烟状态。次要结局包括自开始服用盐酸安非他酮缓释片治疗以来报告的不良和戒烟效果。
在3个月时,服用较大剂量盐酸安非他酮缓释片的人群中观察到显著更高的戒烟率(P = 0.005)。在12个月时,中等强度咨询与显著更高的戒烟率相关(P = 0.001)。在3个月时,较高剂量与自我报告症状的频率显著增加相关,如睡眠困难(P = 0.02)、注意力不集中(P = 0.02)、颤抖/震颤(P = 0.002)和胃肠道问题(P = 0.005),以及报告的吸烟欲望频率降低(P = 0.001)。
在这个实际临床环境中,盐酸安非他酮缓释片与最低或中等咨询相结合的1年戒烟率为23.6%至33.2%。这表明,如果现有医疗保健系统提供这些适度的干预措施,它们可以大幅降低其参保人群中的烟草使用率。